Xilio Therapeutics, Inc.
XLO- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001840233
No open-market purchases or sales by Xilio Therapeutics, Inc. insiders were filed in the last 90 days; 27 institutions reported holding it in 13F filings for Q2 2026, worth $32.6M in total; no superinvestor holds it.
13F holders, Q1 2023
Institutional positions in Xilio Therapeutics, Inc. as of Mar 31, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 32
- +4 vs. Q4 2022
- Shares held
- 16.1M
- +145.5K (+0.9%) vs. Q4 2022
- Total value
- $51.0M
- +$8.14M (+19.0%) vs. Q4 2022
- New holders
- 4
- 6 more added
- Sold out
- 0
- 3 more reduced
Compare with Q4 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting XLO on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 27 | $32.6M |
| Q1 2026 | 24 | $22.0M |
| Q4 2025 | 37 | $25.4M |
| Q3 2025 | 36 | $18.6M |
| Q2 2025 | 35 | $16.2M |
| Q1 2025 | 35 | $16.3M |
| Q4 2024 | 35 | $24.7M |
| Q3 2024 | 33 | $12.6M |
| Q2 2024 | 32 | $13.7M |
| Q1 2024 | 31 | $13.5M |
| Q4 2023 | 34 | $9.03M |
| Q3 2023 | 31 | $33.5M |
| Q2 2023 | 32 | $41.9M |
| Q1 2023 | 32 | $51.0M |
| Q4 2022 | 28 | $42.8M |
| Q3 2022 | 29 | $48.3M |
| Q2 2022 | 33 | $52.2M |
| Q1 2022 | 41 | $132.7M |
| Q4 2021 | 42 | $303.1M |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q1 2023
Shares, value and share of portfolio for each institution holding Xilio Therapeutics, Inc.; share changes are against Q4 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Wells Fargo & Company | 78 | $247 | 0.00% | +1+1.3% | Added |
| UBS Group AG | 201 | $637 | 0.00% | 00.0% | Unchanged |
| Royal Bank of Canada | 731 | $2.00K | 0.00% | +731 | New |
| Key Financial Inc | 830 | $2.63K | 0.00% | +830 | New |
| JPMorgan Chase & Co | 2,701 | $9.00K | 0.00% | 00.0% | Unchanged |
| Tower Research Capital LLC (TRC) | 4,591 | $15.0K | 0.00% | +332+7.8% | Added |
| Nwam LLC | 10,000 | $31.7K | 0.00% | 00.0% | Unchanged |
| State Street Corp | 15,690 | $49.9K | 0.00% | 00.0% | Unchanged |
| Millennium Management LLC | 16,746 | $53.0K | 0.00% | −10,146−37.7% | Reduced |
| Northern Trust Corp | 16,897 | $53.6K | 0.00% | +3,997+31.0% | Added |
| Cannell Capital LLC | 17,025 | $54.0K | 0.01% | 00.0% | Unchanged |
| Dimensional Fund Advisors LP | 17,881 | $56.9K | 0.00% | +17,881 | New |
| Renaissance Technologies LLC | 18,800 | $60.0K | 0.00% | −18,300−49.3% | Reduced |
| Morgan Stanley | 30,539 | $96.8K | 0.00% | +4,928+19.2% | Added |
| BlackRock Inc. | 51,005 | $161.7K | 0.00% | +1,566+3.2% | Added |
| Citadel Advisors LLC | 71,635 | $227.8K | 0.00% | +71,635 | New |
| Geode Capital Management, LLC | 84,726 | $269.4K | 0.00% | 00.0% | Unchanged |
| Bridgeway Capital Management, LLC | 110,481 | $351.3K | 0.01% | 00.0% | Unchanged |
| Laurion Capital Management LP | 142,900 | $454.4K | 0.02% | 00.0% | Unchanged |
| FIL Ltd | 218,705 | $695.5K | 0.00% | 00.0% | Unchanged |
| Soleus Capital Management, L.P. | 226,941 | $719.4K | 0.09% | 00.0% | Unchanged |
| Bank of America Corp | 227,276 | $720.5K | 0.00% | −5,792−2.5% | Reduced |
| Trustees of Columbia University in the City of New York | 249,635 | $791.3K | 1.42% | 00.0% | Unchanged |
| Harvard Management Co Inc | 416,059 | $1.32M | 0.14% | 00.0% | Unchanged |
| Artal Group S.A. | 450,000 | $1.43M | 0.08% | 00.0% | Unchanged |
| Vanguard Group Inc | 890,353 | $2.82M | 0.00% | 00.0% | Unchanged |
| Rock Springs Capital Management LP | 1,440,759 | $4.57M | 0.11% | +77,881+5.7% | Added |
| RiverVest Venture Management LLC | 1,441,444 | $4.57M | 5.29% | 00.0% | Unchanged |
| FMR LLC | 1,907,671 | $6.07M | 0.00% | 00.0% | Unchanged |
| Octagon Capital Advisors LP | 2,425,000 | $7.69M | 1.11% | 00.0% | Unchanged |
| Atlas Venture Life Science Advisors, LLC | 2,759,344 | $8.75M | 1.18% | 00.0% | Unchanged |
| Bain Capital Life Sciences Investors, LLC | 2,805,413 | $8.89M | 1.11% | 00.0% | Unchanged |